Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L21 pseudogene 46 (RPL21P46) is a processed pseudogene related to the ribosomal protein L21 gene family[2][7]. Unlike functional ribosomal proteins (such as RPL21), this pseudogene does not produce a functional protein and has no known biological function, disease association, or therapeutic relevance[7]. In humans, processed pseudogenes like RPL21P46 are common due to gene duplication events but are usually not transcribed or translated into proteins[3][5][7]. The canonical ribosomal protein L21 (RPL21), to which it is related, is a structural component of the large ribosomal 60S subunit, but RPL21P46 itself is not functional[3][5][7]. This is not a therapeutic target—it is a pseudogene, lacking protein-coding function and any known significance as a receptor, enzyme, transporter, or drug target. The entry is technically correct as a gene symbol but incorrect as a therapeutic target or functional molecule[7][2].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 46 (RPL21P46).